TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Luye Pharma Group ( (HK:2186) ) is now available.
Luye Pharma Group Ltd. has received FDA clearance to initiate clinical trials in the U.S. for its new drug LY03017, designed to treat Alzheimer’s disease psychosis, Parkinson’s disease psychosis, and negative symptoms of schizophrenia. This development highlights the company’s strategic focus on CNS diseases and its commitment to addressing unmet medical needs in these areas, potentially enhancing its market position and offering new treatment options for patients globally.
The most recent analyst rating on (HK:2186) stock is a Hold with a HK$3.50 price target. To see the full list of analyst forecasts on Luye Pharma Group stock, see the HK:2186 Stock Forecast page.
More about Luye Pharma Group
Luye Pharma Group Ltd. is a pharmaceutical company focused on developing innovative therapies for central nervous system (CNS) diseases. Their portfolio includes treatments for major depressive disorder, schizophrenia, bipolar disorder, and Alzheimer’s disease, with several products approved for marketing in the U.S., Europe, Japan, and China.
YTD Price Performance: 36.41%
Average Trading Volume: 41,920,099
Technical Sentiment Signal: Sell
Current Market Cap: HK$11.63B
Learn more about 2186 stock on TipRanks’ Stock Analysis page.